Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7568273 | 0.98 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTKDM4EGAA | |
| SCHEMBL22567048 | 0.88 | CA12 (0.43) | ALDH1A1LMNAMAPTKDM4EGAA | |
| SCHEMBL1596452 | 0.84 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTKDM4EGAA | |
| SCHEMBL1597018 | 0.82 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTKDM4EGAA | |
| SCHEMBL5047229 | 0.80 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTKDM4EGAA | |
| SCHEMBL11850699 | 0.80 | LMNA (0.70) | ALDH1A1LMNAMAPTKDM4EGAA | |
| SCHEMBL18827165 | 0.80 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTKDM4EGAA | |
| SCHEMBL21501141 | 0.80 | AKR1C3 (0.49) | ALDH1A1LMNAMAPTKDM4EGAA | |
| SCHEMBL651902 | 0.79 | ALDH1A1 (0.71) | ALDH1A1LMNAGAAHSD17B10TDP1 | |
| SCHEMBL1029776 | 0.79 | TRPV4 (0.42) | ALDH1A1LMNAMAPTKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 796 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258343-B2 | Method for preparing 2-[(3R)-3-methylmorpholin-4-yl]-4-[1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-25 | — | — | US | claimed |
| CN-112823158-B | Process for preparing 2- [ (3R) -3-methylmorpholin-4-yl ] -4- (1-methyl-1H-pyrazol-5-yl) -8- (1H-pyrazol-5-yl) -1, 7-naphthyridine | 拜耳股份有限公司 | 2023-08-15 | — | — | CN | claimed |
| EP-3841101-B1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | BAYER AG (DE) | 2023-05-03 | — | — | EP | claimed |
| US-20210253573-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-19 | — | — | US | claimed |
| EP-3841101-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | Bayer Aktiengesellschaft (DE) | 2021-06-30 | — | — | EP | claimed |
| CN-112823158-A | Process for the preparation of 2- [ (3R) -3-methylmorpholin-4-yl ] -4- (1-methyl-1H-pyrazol-5-yl) -8- (1H-pyrazol-5-yl) -1, 7-naphthyridine | 拜耳股份有限公司 | 2021-05-18 | — | — | CN | claimed |
| WO-2020039025-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | BAYER AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | WO | claimed |
| CN-103374088-B | A kind of ethylene-alpha-olefin copolymer and preparation method thereof | SINOPEC CORP. (CN) | 2015-09-16 | — | — | CN | claimed |
| CN-104678028-A | Pretreatment and detection method for biogen amine neurotransmitter and detection kit | INST PHARM & TOXICOLOGY AMMS | 2015-06-03 | — | — | CN | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| EP-0873334-A1 | PROCESS FOR THE PREPARATION OF AN ENDOTHELIN ANTAGONIST | Merck & Co., Inc. (a New Jersey corp.) (US) | 1998-10-28 | — | — | EP | claimed |
| US-5688974-A | Process for the preparation of an endothelin antagonist | MERCK & CO., INC. (US) | 1997-11-18 | — | — | US | claimed |
| WO-1997021700-A1 | PROCESS FOR THE PREPARATION OF AN ENDOTHELIN ANTAGONIST | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | claimed |
| US-4168375-A | Process for the recovery of cephalosporin C and derivatives thereof | ALFA FARMACEUTICI, S.P.A. (IT) | 1979-09-18 | — | — | US | claimed |
| WO-2026104676-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026104681-A1 | NEW SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026104679-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| US-4168375-A | Process for the recovery of cephalosporin C and derivatives thereof | ALFA FARMACEUTICI, S.P.A. (IT) | 1979-09-18 | — | — | US | disclosed |
| US-4107065-A | P-ACYLAMINOBENZENESULFONYL CHLORIDE OR BROMIDE | COLGATE-PALMOLIVE COMPANY (US) | 1978-08-15 | — | — | US | disclosed |
| US-4041051-A | 1-AMINO-4-HYDROXY-2-(P-METHOXY OR ETHOXY-BENZENESULFONYLOXY)-ANTHRAQUINONE | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258343-B2 | Method for preparing 2-[(3R)-3-methylmorpholin-4-yl]-4-[1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine | CYP1B1, CYP4B1, CYP1A1 | ALDH1A1 432/4885LMNA 793/4885MAPT 2788/4885 |
| US-20210253573-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | CYP1B1, CYP4B1, CYP1A1 | ALDH1A1 432/4885LMNA 793/4885MAPT 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.